Two companies were added to Russell 3000 indexes today: Uroplasty Inc. (NSDQ:UPI) joined the global index, and Delcath Systems Inc. (NSDQ:DCTH) joined the lower third of the U.S. index.
Delcath Systems Inc.
Winner Medical replaces “Tony” with “Rocky” | Personnel Moves
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
FDA approves spine sealant from Covidien | Regulatory roundup
Here’s a roundup of companies announcing clearances and approvals from the FDA and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.
Bupp steps down as Neoprobe CEO | Personnel moves
Neoprobe Corp. (NYSE Amex:NEOP) is getting a new chief executive and, perhaps, a new board member.
The Dublin, Ohio-based cancer diagnostics firm announced that CEO David Bupp will be replaced by chief development officer Mark Pykett on April 15.
Gore wins European approval for vascular graft | Regulatory roundup
Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.
Delcath completes $33.8 million offering
After raking in $33.8 million, Delcath Systems Inc. (NSDQ:DCTH) closed its public offering of 5.2 million shares.
According to a Securities & Exchange Commission filing, the New York-based company plans to use the proceeds from the sale to fund "clinical trials, research & development, obtaining regulatory approvals, manufacturing, operations, sales, commercialization of its products and other general corporate purposes including capital expenditures and working capital."